14 February 2013Americas

Bristol-Myers Squibb loses Baraclude patent fight with Teva

A US judge has invalidated pharmaceutical company Bristol-Myers Squibb (BMS)’s patent covering its hepatitis B treatment Baraclude, agreeing with generic manufacturer Teva Pharmaceuticals that the invention of the active compound in the drug was obvious to anyone skilled in medicinal chemistry.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk